LPCN

Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company founded and headquartered in Salt Lake City, Utah. The company went public in October 2013 and specializes in developing oral delivery solutions for pharmaceutical products that treat neuroendocrine and metabolic disorders. Lipocine's core focus is on creating oral formulations of drugs that traditionally have poor bioavailability when taken by mouth, particularly hormone-based therapies. The company's lead product, TLANDO, is an oral testosterone replacement therapy that has received FDA approval, representing a significant milestone in the company's development trajectory.